In the quest to provide treatment for COVID-19 patients, available therapies that have been approved for other indications but have insufficient evidence of safety and efficacy for use against COVID-19 have been considered. One of the unintended consequences of this approach is the potential creation of shortages, depriving existing patients who are benefiting from products based on their proven indications. Here, a pharmaceutical company outlines their ethical decision-making framework to guide decision-making and ensure equity of access to products.
Arthur L. Caplan, Joanne Waldstreicher, Karla Childers, Aran Maree
Usage data is cumulative from September 2020 through September 2020.
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.